Monitor future Form 4 filings for any open-market purchases or sales by Barry Greene, which would provide a clearer signal of insider conviction. The vesting schedule suggests a long-term retention incentive.
Price Chart
Executive Summary
Barry Greene filed an initial statement of beneficial ownership (Form 3) with the SEC, reporting a stock option grant for 59,878 shares of City Therapeutics common stock at an exercise price of $0.92 per share. The option vests in 48 equal monthly installments starting September 29, 2024, subject to continued service. This is a routine insider filing with no material financial impact.
Key Facts
- Barry Greene filed a Form 3 initial statement of beneficial ownership for City Therapeutics, Inc. (CTY).
- Greene reported a stock option to buy 59,878 shares of common stock at an exercise price of $0.92 per share.
- The option vests in 48 equal monthly installments beginning September 29, 2024, subject to continued service.
- The filing includes a power of attorney appointing Sebastian Trousil and Mary Beth DeLena to execute future Forms 3, 4, and 5.
Financial Impact
No immediate financial impact. The option grant is a standard equity incentive for a new insider.
Risk Factors
- No material risks identified from this routine filing.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001104659-26-116348 |
| Document: 0001104659-26-116348-index-headers.html | 0001104659-26-116348 |
| Document: 0001104659-26-116348-index.html | 0001104659-26-116348 |
| Document: 0001104659-26-116348.txt | 0001104659-26-116348 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | SC 13D | $20.79 | awaiting T+5 | — | $20.86 (+0.34%) |
Oct 26, 2026 1d ago | SC 13G | $20.79 | awaiting T+5 | — | $20.86 (+0.34%) |
Oct 22, 2026 5d ago | SC 13G | $20.77 | awaiting T+5 | — | $20.86 (+0.43%) |
Oct 19, 2026 8d ago | Insider Cluster | $20.83 $20.86 | ▲ +0.14% | ▲ +0.06% | $20.86 (+0.14%) |
Oct 19, 2026 8d ago | Press Release | $20.83 $21.19 | ▲ +1.73% | ▲ +1.70% | $20.86 (+0.14%) |
Oct 16, 2026 11d ago | 424B4 | $21.46 $20.79 | ▼ −3.12% | ▼ −2.98% | $20.86 (−2.80%) |
Oct 16, 2026 11d ago | EFFECT | $22.40 $20.77 | ▼ −7.28% | ▼ −6.85% | $20.86 (−6.87%) |
Oct 15, 2026 12d ago | 3 | $22.40 $20.77 | ▼ −7.28% | ▼ −6.85% | $20.86 (−6.87%) |
Oct 15, 2026 12d ago | 3 | $22.40 $20.77 | ▼ −7.28% | ▼ −6.85% | $20.86 (−6.87%) |
Oct 15, 2026 12d ago | 3 | $22.40 $20.77 | ▼ −7.28% | ▼ −6.85% | $20.86 (−6.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers